|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 21, 2002; DOI 10.1182/blood-2002-07-2247.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Dermatology, and Department of
Bone Marrow Transplantation, The University of Texas MD Anderson Cancer
Center, Houston.
Although mycosis fungoides (MF) may arise through persistent
antigen stimulation, cytomegalovirus (CMV) is not a known risk factor.
To study the incidence of seropositivity to viral infections, we
compared MF and Sézary Syndrome (SS) patients to healthy bone marrow donors and other historical control groups. Baseline screening serologies at baseline were performed on 116 biopsy-proven MF/SS patients at MD Anderson Cancer Center from 1992 to 2001 and on healthy
bone marrow donors evaluated by the transplant service from 1988 to
2001. Antibodies to HTLV-I/II, HIV-1, EBV, and CMV were measured using
standard enzyme-linked immunosorbent (ELISA) and membrane enzyme
immunoassay (MEIA) assays. One hundred thirteen (97.4%) of all MF/SS
patients had positive CMV IgG serologies at initial presentation.
Early- and late-stage patients' seropositivity rates were
significantly higher than healthy bone marrow donor controls
( Cutaneous T-cell lymphomas (CTCLs) are clonal T-cell malignancies with
primary cutaneous manifestations. The most common variant of CTCL is
mycosis fungoides (MF), an indolent lymphoma characterized histologically by atypical epidermotropic CD4+
helper/CD45Ro+ memory T-cell clones. Sézary syndrome
(SS) is the erythrodermic, leukemic variant of MF.1 MF is
hypothesized to arise through persistent antigenic stimulation, leading
to an accumulation of skin-homing T cells that are defective in
apoptotic programmed cell death.2,3 Although viruses are
known to provide chronic immune stimulation, cytomegalovirus (CMV) has
not previously been identified as a risk factor for MF/SS.
Human cytomegalovirus (CMV) is a member of the herpes family of
viruses. Primary infection is followed by latency. Polymorphonuclear leukocytes, T cells, endothelial cells, and salivary glands have all
been shown to harbor CMV in latent form.4 Active CMV
infection causes characteristic changes in specific lymphocyte
populations, ie, CD8+ T-cell lymphocytes and natural killer
(NK) cells.5,6 CMV has an array of immune escape
strategies for establishing life-long latency. CMV inhibits major
histocompatibility complex (MHC) class I expression within infected
cells and impairs MHC class II-dependent antigen presentation by
macrophages.7 It also encodes proteins that interfere with
the presentation of viral peptide antigens to T cells.
CMV is a common opportunistic pathogen in both the transplant and human
immunodeficiency virus-infected (HIV+) populations,
reflecting the T-cell deficiency in these patients.8 Patients with CTCL also have profound immunodeficiency in later stages
of the disease with diminished T-cell function and disappearance of the
CD8 cytotoxic population.9 Infectious syndromes resulting from CMV in immunocompromised hosts include pneumonitis,
gastroenteritis, hepatitis, pancreatitis, encephalitis, retinitis, and
bone marrow suppression. CMV-induced skin lesions are nonspecific and
generally localized and ulcerative or are generalized and
maculopapular.10 In patients receiving solid-organ
transplants, CMV infection causes direct injury to transplanted organs
and contributes to both acute and chronic transplant
rejection.11 CMV has been implicated in the development of
accelerated atherosclerosis in the coronary arteries of transplanted
hearts.12 In healthy individuals, infection manifests most
commonly as a self-limited mononucleosislike syndrome or is entirely
asymptomatic. The seropositivity rate in the general population is
generally increased with parity and age.
Study population
Serology testing methods
Statistical analyses Chi-square analyses using 2 × 2 tables were performed to compare CMV seropositivity in all CTCL patients, in early-stage patients, and in late-stage patients with healthy bone marrow control subjects. In order for a chi-square value to be significant with one degree of freedom, and P = .05, that value must be more than 3.841.In addition, chi-square analysis and independent samples t test were used to compare CMV seropositivity in CTCL patients aged 55 years or younger with bone marrow donors aged 55 years or younger.
The demographics of the patients with CTCL between 1992 and the
present who had prospective evaluations done at baseline for CMV
seropositivity are shown in Table 1. Of 116 MF/SS CTCL patients, 113 (97.4%) had positive CMV-IgG serologies, including 59 men and 57 women, and are equally distributed in our population. Only 3 CTCL
patients were found to be seronegative. Those were 2 women and 1 man,
stages IA, IIB, and IVB, respectively (Table
2). Of 53 patients with early-stage MF (IA, IB, IIA), 52 were CMV
seropositive (98.1%). Patients with late-stage MF/SS (IIB-IVB) had a
96.8% (61 of 63) seropositivity rate. In contrast, the seropositivity rate among healthy bone marrow donors evaluated at MD Anderson since
1988 was 57.3% (757 of 1322).
MF/SS patients as a group had a significantly higher rate of CMV
seropositivity compared with healthy control subjects
( We also examined serologies for other viruses such as HIV-1 and viruses
implicated in CTCL and HTLV-I and II.14 One hundred thirteen patients with MF/SS were tested for HIV, and all were negative
by ELISA. Of 114 patients tested for HTLVI/II, only one was positive.
Only 13 patients had EBV serologies drawn, but all were seropositive
(Table
3).
Recognizing that the rate of CMV seropositivity increases with age, we
also compared CMV seropositivity rates in CTCL patients with CTCL
patients that were aged 55 years or younger with age-matched, healthy
bone marrow donors aged 55 years or younger. Again, CMV seropositivity
was significantly higher among "young" CTCL patients compared with
healthy bone marrow donors
(
This study shows for the first time that more than 97% of
patients at all stages of CTCL (MF and SS) have evidence for previous infection with human CMV. The seropositivity rates are significantly higher compared with healthy donor control subjects from bone marrow
transplant donors and are high even in the subset of young patients.
Surprisingly, the rate of seropositivity of CTCL patients exceeded that
of patients who are historically considered to be in high-risk groups,
including homosexual men and patients with HIV/AIDS (Table
4). Patients with CTCL also develop profound immunodeficiency with
disease progression, and their gradual loss of the CD8+
cytotoxic T-cell population is associated with poor prognosis and has
been attributed to the overgrowth of the malignant clone.9 Apoptosis of CD8+ tumor-infiltrating lymphocytes may also
be mediated by tumor cells with Fas ligand (FasL) expression,
resulting in immunosuppression with time.27
Cytomegalovirus is a latent virus and has been implicated in bone marrow suppression and with fatal pneumonia in our transplant population.28 CMV seropositivity is a negative independent prognostic factor for overall survival among patients receiving bone marrow transplants.26 Because CMV seropositivity increases with age, we also examined a subset of the patients and found that the seropositivity rate among younger CTCL patients was 93%, with only 2 of 32 patients seronegative. In fact, only 3 patients in the entire cohort were negative for CMV. We also examined the rate of Epstein-Barr virus seropositivity in the same group of patients. Of the 13 patients in the group who were tested, all 13 were positive. Viruses have been implicated in a variety of autoimmune diseases and may share host antigens (molecular mimicry), resulting in inappropriate immune stimulation against host proteins. Autoimmune diseases are almost always associated with certain human histocompatibility antigens thought to confer disease susceptibility or be correlated with the development of specific antibodies.29 Epstein-Barr virus infection has been previously implicated in several kinds of lymphomas, including Hodgkin disease, Burkitt lymphoma, NK-T nasopharyngeal tumors, peripheral T-cell lymphomas, and posttransplantation lymphoproliferative disorders.30,31 EBV is also associated with autoimmune diseases such as childhood lupus erythematosus and rheumatoid arthritis.32 HTLV-1 is found in adult T-cell lymphoma and leukemia, and it has been implicated by several studies in CTCL.33-35 Others have not been able to confirm this finding.36,37 In this study, all except one of the patients with CTCL had negative HTLV-1 serology studies at baseline. We have previously shown that patients with MF and SS have a significant association with major histocompatibility class II HLA-DR5 (w11) and HLA-DQB*03 alleles.38 Staphylococcal superantigens were also commonly associated with erythrodermic MF/SS patients in our previous study and can stimulate proliferation of CTCL cells.3,39 The HLA-DR5 allele is also associated with melanoma progression, scleroderma, Hashimoto thyroiditis, and alopecia areata,40 all characterized by a T-cell-mediated immune response. Of interest, the DR5 antigen is also exquisitely sensitive to stimulation by staphylococcal superantigen.41 HLA alleles may also influence the incidence of CMV infection and subsequent seropositivity within a population group.42 A chlamydia-related factor found to stimulate proliferation of Sézary cells led to the finding of chlamydia organisms within MF lesions and has been suggested to contribute to the pathogenesis of MF/SS as a persistent antigen.43 Chlamydia organisms and also CMV have been implicated in inflammation initiating coronary artery disease.44 However, in one study of angiography patients in Spain, 97% had CMV seropositivity regardless of the presence of atherosclerotic plaques at catherization.45 A prospective, well-designed case-control study of healthy postmenopausal women with (n = 122) and without (n = 244) coronary artery disease (CAD) also found no significant differences in seropositivity rates for CMV, Chlamydia, and Helicobacter pylori.46 Thus, there is conflicting data on the role of infectious agents in mediating the chronic inflammation that is associated with both MF and atherosclerosis. Risk factors for CMV infection reported in the literature include age, number of children, and immune status. Patients with HIV or allogeneic stem cell transplants (ie, T-cell deficiencies) are highly susceptible to CMV infection and may succumb to it.8 In patients with CTCL, there was no evidence for active CMV infection. In addition, most of the patients were not immunosuppressed and would be expected to have a rate of seropositivity equal to age-matched healthy controls. However, CMV IgG seropositivity is highly associated with MF and SS even in the earliest stages of the disease, when compared with healthy control subjects as well as various historical groups reported in the literature that are listed in Table 4. One variable is that the median age of our patient population was higher than all control groups, including bone marrow donors and patients with HIV and CAD. However, when we considered the CTCL patients younger than age 55 separately, 93% (30 of 32) were CMV seropositive and also were significantly higher than age-matched controls. Of the 28 patients with stage IA MF and only minor skin involvement, 27 were positive for CMV, making it unlikely that the cutaneous disease predisposed these patients to serologic conversion. Of the 3 seronegative patients, 2 presented before age 25. One was a 21-year-old black woman with stage IVB MF whose course was characterized by persistent Staphylococcus aureus and mucocutaneous candidiasis infections. Her CTCL has been refractory to multiple treatment modalities. Another seronegative female patient presented with stage IIB rapidly progressive disease and succumbed at age 23 during bone marrow transplantation from staphylococcal sepsis. The third seronegative patient was a 59-year-old man with stage IA disease who had long-term remission with conservative topical therapy. When compared with historical control groups reported in the literature (Table 4), patients with CTCL exceed seropositivity rates of virtually all groups reported. We were intrigued to find that CMV seropositivity was higher than in high-risk groups such as HIV+ men (86%),23 health care workers caring for children (44.5%), immunocompromised patients (43.6%),18 and patients with coronary artery disease (54.5%).24 Even patients with early-stage MF with normal immune systems and minimal skin involvement have significantly higher CMV seropositivity rates than do control subjects, and they are similar to late-stage patients who tend to become immunocompromised with disease state and therapy. The significance of this observation is not clear. Latent CMV and/or EBV infection could play a potential role in the susceptibility to or pathogenesis of CTCL. They could provide chronic antigen stimulation, induce T-cell proliferation, and adversely affect apoptosis of skin-homing memory/helper T-cells.
Submitted July 25, 2002; accepted October 20, 2002.
Prepublished online as Blood First Edition Paper, November 21, 2002; DOI 10.1182/blood-2002-07-2247.
Supported in part by grants K24 86815 (National Institutes of Health) and CA16672 (National Cancer Institute) and by the Sherry L. Anderson CTCL Research Fund.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Presented in part at the 43rd annual meeting of the American Society of Hematology, Orlando, FL, December 8-11, 2001, and at the annual meeting of the American Academy of Dermatology, New Orleans, LA, February 24-28, 2002. Reprints: Madeleine Duvic, The University of Texas MD Anderson Cancer Center, Department of Dermatology, Box 434, 1515 Holcombe Blvd, Houston, TX 77030-4095; e-mail: mduvic{at}mdanderson.org.
1. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol. 1999;26:276-281[Medline] [Order article via Infotrieve].
2.
Tan RSH, Butterworth CM, McLaughlin H, Malka S, Samman PD.
Mycosis fungoides
3.
Jackow CM, Cather JC, Hearne V, Asano A, Musser JM, Duvic M.
Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion.
Blood.
1997;89:32-39 4. Crumpacker C. Cytomegalovirus Mandell's Principles and Practice of Infectious Disease. 5th ed. Philadelphia, PA: Churchill-Livingstone; 2000:1586-1596. 5. Khan N, Cobbold M, Keenan R, Moss P. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis. 2002;185:1025-1034[CrossRef][Medline] [Order article via Infotrieve]. 6. Nyquist AC, Zhang L, Wienberg A. Human fibroblasts transfected with cytomegalovirus immediate-early genes show increased MHC class I expression and are targets for natural killer cell mediated toxicity. Viral Immunol. 2002;15:147-154[CrossRef][Medline] [Order article via Infotrieve]. 7. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompromised individuals. J Dermatol Sci. 2000;22:196-204[CrossRef][Medline] [Order article via Infotrieve].
8.
Holmberg L, Boeckh M, Hooper H, et al.
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplant.
Blood.
1999;94:4029-4035 9. Wood GS, Edinger A, Hoppe RT, Warnke RA. Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T lymphocyte phenotype. J Cutan Pathol. 1994;21:151-156[CrossRef][Medline] [Order article via Infotrieve]. 10. Lopez FA, Sanders CV. Dermatologic infection in the immunocompromised (non-HIV) host. Infect Dis Clin North Am. 2001;15:671-702[CrossRef][Medline] [Order article via Infotrieve]xi. 11. Becker B, Becker Y, Leverson G, Simmons W, Sollinger H, Pirsch J. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis. 2002;39:1088-1095[CrossRef][Medline] [Order article via Infotrieve]. 12. Hosenpud J. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J. 1999;138:S469-S472[CrossRef][Medline] [Order article via Infotrieve]. 13. Bunn PJ, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep. 1997;63:725-733. 14. Zucker-Franklin D, Pancake BA. The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas. Semin Dermatol. 1994;13:160-165[Medline] [Order article via Infotrieve]. 15. De Schryver A, Glazemakers J, De Bacquer D, De Backer G, Lust E. Risk of cytomegalovirus infection among educators and health care personnel serving mentally disabled children. J Infect. 1999;38:36-40[CrossRef][Medline] [Order article via Infotrieve]. 16. Kiss P, De Bacquer D, Sergooris L, De Meester M, VanHoorne M. Cytomegalovirus infection: an occupational hazard to kindergarten teachers of children aged 2.5-6 years. Int J Occup Environ Health. 2002;8:79-86[Medline] [Order article via Infotrieve]. 17. Greenhalgh LF, Miller KF. Donor insemination. Prevalence of antibodies to cytomegalovirus. J Reprod Med. 1997;42:111-113[Medline] [Order article via Infotrieve]. 18. Sobaszek A, Fantoni-Quinton S, Frimat P, Leroyer A, Laynat A, Edme JL. Prevalence of cytomegalovirus infection among health care workers in pediatric and immunosuppressed adult units. J Occup Environ Med. 2000;42:1109-1114[Medline] [Order article via Infotrieve].
19.
Bale JF, Zimmerman B, Dawson JD, Souza IE, Petheram SJ, Murph JR.
Cytomegalovirus transmission in child care homes.
Arch Pediatr Adolesc Med.
1999;153:75-79 20. Nishimura N, Kimura H, Yabuta Y, et al. Prevalence of maternal cytomegalovirus (CMV) antibody and detection of CMV DNA in amniotic fluid. Microbiol Immunol. 1999;43:781-784[Medline] [Order article via Infotrieve]. 21. Berry NJ, Burns DM, Wannamethee G, et al. Seroepidemiologic studies on the acquisition of antibodies to cytomegalovirus, herpes simplex virus, and human immunodeficiency virus among general hospital patients and those attending a clinic for sexually transmitted diseases. J Med Virol. 1988;24:385-393[Medline] [Order article via Infotrieve].
22.
Dylewski JS, Rasmussen L, Mills J, Merigan TC.
Large-scale serological screening for cytomegalovirus antibodies in homosexual males by enzyme-linked immunosorbent assay.
J Clin Microbiol.
1984;19:200-203 23. Holland CA, Ma Y, Moscicki B, Durako SJ, Levin L, Wilson CM. Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high risk adolescents: findings of the REACH study. Sex Transm Dis. 2000;27:296-303[Medline] [Order article via Infotrieve]. 24. Rothenbacher A, Hoffmeister G, Bode G, Wanner P, Koenig W, Brenner H. Cytomegalovirus infection and coronary heart disease: results of a German case-control study. J Infect Dis. 1999;179:690-692[CrossRef][Medline] [Order article via Infotrieve]. 25. Hirata M, Terasaki PI, Cho YW. Cytomegalovirus antibody status and renal transplantation: 1987-1994. Transplantation. 1996;62:34-37[CrossRef][Medline] [Order article via Infotrieve]. 26. Kroger N, Zabelina T, Kruger, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol. 2001;13:1060-1071.
27.
Ni X, Hazarika P, Zhang C, Talpur R, Duvic M.
Fas ligand expression by neoplastic T-lymphocytes mediates elimination of CD8+ cytotoxic T-lymphocytes in mycosis fungoides: a potential mechanism for tumor immune escape?
Clin Cancer Res.
2001;7:2682-2689 28. Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001;27:877-883[CrossRef][Medline] [Order article via Infotrieve].
29.
Sinha AA, Lopez MT, McDevitt HO.
Autoimmune diseases: the failure of self tolerance.
Science.
1990;248:1380-1390 30. Hsu JL. EBV associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34:27-53[Medline] [Order article via Infotrieve]. 31. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 2002;159:9-18[Medline] [Order article via Infotrieve]. 32. Sawada S. Ebstein-Barr virus and rheumatoid arthritis. J Rheumatol. 2001;28:2363-2364[Medline] [Order article via Infotrieve].
33.
Zucker-Franklin D, Hooper WC, Evatt BL.
Human lymphotropic retroviruses associated with mycosis fungoides: evidence that human T-cell lymphotropic virus type II as well as HTLV-1 may play a role in the disease.
Blood.
1992;80:1537-1543 34. Khan ZM, Sebenik M, Zucker-Franklin D. Localization of human T-cell lymphotropic virus-1 tax proviral sequences in skin biopsies of patients with mycosis fungoides by in situ polymerase chain reaction. J Invest Dermatol. 1996;106:667-674[CrossRef][Medline] [Order article via Infotrieve].
35.
Hall WW.
HTLV-1 provirus and mycosis fungoides.
Science.
1993;259:1470-1477 36. Li G, Vowels BR, Benoit BM, Rook AH, Lessin SR. Failure to detect human T-lymphotropic virus type (HTLV-1) proviral DNA in cell lines and tissues from patients with cutaneous-cell lymphoma. J Invest Dermatol. 1996;107:308-312[CrossRef][Medline] [Order article via Infotrieve]. 37. Wood GS, Salvekar A, Schaffer J, et al. Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-1) in the pathogenesis of American cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107:301-308[CrossRef][Medline] [Order article via Infotrieve]. 38. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107:373-379[CrossRef][Medline] [Order article via Infotrieve]. 39. Tokura Y, Heald PW, Yan SL, Edelson RL. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol. 1992;98:33-38[CrossRef][Medline] [Order article via Infotrieve]. 40. Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment. J Am Acad Dermatol. 1998;38:418-423[CrossRef][Medline] [Order article via Infotrieve].
41.
Mollick JA, Cook RG, Rich RR.
Class II molecules are specific receptors for staphylococcus enterotoxin A.
Science.
1989;244:817-822 42. Machida S, Takahashi T, Nomoto K, Murata S. HLA antigens are associated in seronegativity to cytomegalovirus (CMV). Nippon Rinsho. 1998;56:129-134[Medline] [Order article via Infotrieve].
43.
Abrams JT, Vonderheid EC, Kolbe S, Appelt DM, Arking EJ, Balin BJ.
Sezary T-cell activating factor is a chlamydia pneumoniae-associated protein.
Clin Diag Lab Immunol.
1999;6:895-899 44. Song YG, Kwon HM, Kim JM, et al. Serologic and histopathologic study of chlamydia pneumonia infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by chlamydia pneumoniae. Yonsei Med J. 2000;41:319-322[Medline] [Order article via Infotrieve]. 45. Sepulveda MA, Moreu J, Canton T, Pajin F, Rodriguez L. Prevalence of IgG antibodies against cytomegalovirus in patients with angiographically demonstrated coronary atherosclerosis. Enferm Infec Microbiol Clin. 1999;17:386-394[Medline] [Order article via Infotrieve].
46.
Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J.
Baseline IgG antibody titers to chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women.
Ann Intern Med.
1999;131:573-579
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Wabulya, J. Imitola, S. Santagata, and S. Kesari Mycosis Fungoides With Leptomeningeal Involvement J. Clin. Oncol., December 10, 2007; 25(35): 5658 - 5661. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Albano, P. Taylor, R. F. Pass, A. Scaradavou, R. Ciubotariu, C. Carrier, L. Dobrila, P. Rubinstein, and C. E. Stevens Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening Blood, December 15, 2006; 108(13): 4275 - 4282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Gupta, J. Ramble, C. Y. W. Tong, S. Whittaker, and E. MacMahon Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sezary syndrome Blood, February 1, 2006; 107(3): 1241 - 1242. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Girardi, P. W. Heald, and L. D. Wilson The Pathogenesis of Mycosis Fungoides N. Engl. J. Med., May 6, 2004; 350(19): 1978 - 1988. [Full Text] [PDF]
|
|
|
|
|
|
K. Ghosh CMV seropositivity and mycosis fungoides--the Indian perspectives Blood, October 1, 2003; 102(7): 2706 - 2707. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
2.05(df=1) = 71.79). By stage,
98.1% of early-stage MF patients (IA, IB, IIA; 52/53) and 96.8% of
late-stage MF and SS patients (IIB-IVB; 61/63) were seropositive
compared with healthy bone marrow donors whose seropositivity
rate was 57.3% (757/1322). Because the rate of CMV seropositivity
increases with age, a subset of cutaneous T-cell lymphoma (CTCL)
patients 55 years or younger were compared to age-matched healthy donor
controls; their seropositivity rate for CMV was also
significantly higher (
a disease of antigen persistence.
Br J Dermatol.
1974;91:607-611